Welcome to our dedicated page for Beta Bionics SEC filings (Ticker: BBNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Beta Bionics, Inc. (Nasdaq: BBNX) provides access to the company’s official U.S. Securities and Exchange Commission disclosures. As a commercial-stage medical device company focused on the iLet Bionic Pancreas for insulin-requiring people with diabetes, Beta Bionics uses its filings to report financial results, operational metrics, and significant corporate events.
Investors can review current reports on Form 8-K, which the company uses to announce quarterly financial results and other material information. Recent 8-K filings reference press releases detailing net sales, gross margin, operating expenses, net loss, cash and investment balances, and non-GAAP measures such as adjusted EBITDA, along with reconciliations to the most directly comparable GAAP measures.
Filings also describe operational indicators that are central to Beta Bionics’ business, including installed customer base, new patient starts, and the mix of reimbursement between the Durable Medical Equipment channel and the Pharmacy Benefit Plan channel. These disclosures help readers understand how the iLet Bionic Pancreas is being adopted and reimbursed in practice.
In addition, the company has filed 8-Ks to furnish investor and analyst presentations and to summarize “real-world” iLet data. These materials discuss changes from baseline HbA1c to glucose management indicator, hypoglycemia metrics, and outcomes for users transitioning from multiple daily injections or competitive hybrid-closed loop systems, as well as analyses of usage patterns such as “fully-closed loop” operation.
Through its registration of common stock on the Nasdaq Global Market under the symbol BBNX, Beta Bionics is subject to ongoing reporting obligations. On this page, AI-powered tools can assist by summarizing lengthy filings, highlighting key figures and definitions, and helping readers navigate topics such as non-GAAP metrics, risk factor discussions, and descriptions of clinical and real-world data included in exhibits.
For anyone researching BBNX, the SEC filings page is a primary source for understanding the company’s reported financial condition, regulatory communications, and the detailed context behind its press releases and investor materials.
Beta Bionics, Inc. Chief Financial Officer Stephen Feider reported both stock awards and a small share sale. On February 27, 2026, he received 131,543 shares of common stock as restricted stock units and an option for 70,831 shares that vests in 36 equal monthly installments starting March 1, 2026. On March 2, 2026, he sold 1,428 shares of common stock at a weighted average price of $12.3616 to cover tax withholding obligations related to restricted stock unit vesting, and held 172,729 common shares directly afterward.
Beta Bionics, Inc. President & CEO Sean Saint reported a mix of equity awards and a small tax-related share sale. On February 27, 2026, he acquired 343,269 shares of common stock as a restricted stock unit award under the 2025 Equity Incentive Plan and received an employee stock option for 184,837 shares, which vests in 36 equal monthly installments starting March 1, 2026. On March 2, 2026, he sold 3,384 shares of common stock in an open-market transaction at a weighted average price of $12.3616, solely to cover tax withholding obligations from restricted stock unit vesting, and held 437,809 common shares directly afterward.
Beta Bionics, Inc. filed a shelf registration on Form S-3 to register securities for future offerings.
The prospectus describes that the company may offer common stock, preferred stock, debt securities and warrants from time to time, and that net proceeds are intended for general corporate purposes, including research and development, product enhancements and working capital. The company’s common stock trades on the Nasdaq Global Market under the symbol BBNX, and the prospectus cites a last reported sale price of $13.67 per share on February 23, 2026.
Beta Bionics, Inc. files its annual report outlining a fast-growing, but still early-stage, diabetes device business built around the iLet Bionic Pancreas. The iLet, an FDA-cleared fully closed-loop insulin delivery system for type 1 diabetes, launched commercially in May 2023 and reached an installed base of 35,011 devices as of December 31, 2025.
The company targets a large U.S. market of 1.9 million people with type 1 diabetes and an estimated 1.9 million insulin-intensive type 2 patients, aiming to simplify care by removing carb counting and manual dosing. Its strategy centers on focused U.S. commercialization, multi-channel reimbursement through both durable medical equipment and pharmacy benefits, and extensive third-party payor contracting.
Beta Bionics is investing in a pipeline that includes Mint, a tubeless patch pump aimed at a pharmacy-channel, pay-as-you-go model, and a bihormonal iLet system that delivers both insulin and glucagon, developed with Xeris. It also maintains key integrations with DexCom and Abbott CGM systems and holds a sizable patent estate, but highlights significant risks around continued losses, funding needs, competition from larger pump makers, regulatory obligations, product reliability, cybersecurity, and dependence on single-source suppliers and external partners.
Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen report shared beneficial ownership of 2,290,023 shares of Beta Bionics common stock, representing 5.2% as of February 20, 2026.
The filing states these Reporting Persons hold the shares through Point72 Associates, LLC, with shared voting and dispositive power of 2,290,023 shares. The cover page figures are reported as of the close of business on February 20, 2026.
Beta Bionics, Inc. reported sharp growth for the fourth quarter and full year 2025 while remaining loss-making. Full-year net sales reached $100.3 million, up 54% from $65.1 million, driven by both Durable Medical Equipment and Pharmacy Benefit Plan channels. Fourth-quarter net sales were $32.1 million, up 57% year over year.
Gross margin improved modestly to 55.4% for 2025. The installed customer base rose to 35,011 users, up 129%, with 19,713 new patient starts, a 52% increase. A high-20s percentage of 2025 new patient starts and a low-30s percentage in the fourth quarter were reimbursed through the PBP channel, showing rapid pharmacy channel expansion.
The company still posted a full-year net loss of $73.2 million, or $1.81 per share, with adjusted EBITDA of negative $52.8 million. Beta Bionics ended 2025 with $264.7 million in cash, cash equivalents, and investments and issued 2026 guidance for revenue of approximately $130 million to $135 million and gross margin of 55.5% to 57.5%.
Beta Bionics, Inc. (BBNX) had a significant shareholder position reported by RTW Investments, LP and its managing partner, Roderick Wong, M.D. The reporting group beneficially owns 2,500,000 shares of common stock, representing 5.7% of the company.
This ownership percentage is based on 44,024,631 shares outstanding as of October 24, 2025, as cited from the company’s Form 10-Q. All 2.5 million shares are held by RTW-managed funds, with RTW and Dr. Wong having shared voting and investment power and no sole voting or dispositive power.
The securities are certified as being held in the ordinary course of business, without the purpose or effect of changing or influencing control of Beta Bionics. The RTW funds are entitled to receive dividends and proceeds from any sale of these shares.
Soleus Capital-affiliated funds and Guy Levy filed an amended Schedule 13G reporting their beneficial ownership of Beta Bionics, Inc. common stock. As of the share count in the issuer’s Form 10-Q, Soleus Capital Management, L.P. and Soleus GP, LLC each report beneficial ownership of 2,503,778 shares, or 5.7% of the company’s common stock. Guy Levy reports beneficial ownership of 2,534,565 shares, or 5.8%, including 30,787 shares over which he has sole voting and dispositive power and the balance on a shared basis through the Soleus funds. Several Soleus entities and Mr. Levy expressly disclaim beneficial ownership of shares held by the funds except for purposes of Section 13(d), and they certify the holdings are not for the purpose of changing or influencing control of Beta Bionics.
Wellington Hadley Harbor Aggregator IV, L.P. reports that it no longer beneficially owns any shares of Beta Bionics, Inc. common stock. The amended Schedule 13G shows 0 shares beneficially owned, representing 0.0% of the class, with no sole or shared voting or dispositive power.
The filing notes that any securities previously held were not acquired or held for the purpose of changing or influencing control of Beta Bionics. Wellington certifies this change in ownership status as of 12/31/2025, formally confirming it is now below the 5% reporting threshold.
Beta Bionics, Inc. (BBNX) received an amended Schedule 13G from Wellington Management Group LLP and related entities showing they no longer hold a reportable stake in the company. As of 12/31/2025, Wellington Management Group LLP, Wellington Group Holdings LLP, and Wellington Investment Advisors Holdings LLP each report 0.00 shares of Beta Bionics common stock, representing 0.0% of the outstanding class, with no sole or shared voting or dispositive power.
The filing explains that any Beta Bionics shares covered by this schedule are owned of record by clients of various Wellington investment advisers, and no single client is known to hold more than five percent of the common stock. Wellington also certifies that any securities were acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of Beta Bionics.